

# **BAISHIDENG PUBLISHING GROUP INC**

8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wignet.com http://www.wignet.com

### ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 32280

Title: Indoleamine 2, 3-dioxygenase: As a potential prognostic marker and

immunotherapeutic target for hepatocellular carcinoma

Reviewer's code: 00503536 Reviewer's country: Japan Science editor: Yuan Qi

**Date sent for review: 2017-01-03 16:43** 

Date reviewed: 2017-01-14 09:05

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[ ] Grade B: Minor language	[ ] The same title	[ ] High priority for
[Y] Grade C: Good	polishing	[ ] Duplicate publication	publication
[ ] Grade D: Fair	[ ] Grade C: A great deal of	[ ] Plagiarism	[ ] Rejection
[ ] Grade E: Poor	language polishing	[Y]No	[Y] Minor revision
	[ ] Grade D: Rejected	BPG Search:	[ ] Major revision
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[ Y ] No	

### **COMMENTS TO AUTHORS**

The review summarized by Asghar et al. describes the role of indoleamine 2, 3-dioxygenase (IDO) in the pathogenesis of HBV- or HCV-associated hepatitis and hepatocarcinogenesis. The review is well written, but has some concerns that need to be addressed. Major points 1, Introduction is too long and contains specific statements regarding IDO in the pathogenesis of hepatitis B and C or hepatocellular carcinoma, which should be described in an independent chapter. 2. The title states that IDO is a prognostic marker, but there are few data or descriptions to support that point.



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## **ESPS PEER-REVIEW REPORT**

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 32280

Title: Indoleamine 2, 3-dioxygenase: As a potential prognostic marker and

immunotherapeutic target for hepatocellular carcinoma

Reviewer's code: 03262371 Reviewer's country: Iran Science editor: Yuan Qi

**Date sent for review: 2017-01-03 16:43** 

Date reviewed: 2017-01-26 10:46

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[ ] Accept
[Y] Grade B: Very good	[ ] Grade B: Minor language	[ ] The same title	[ ] High priority for
[ ] Grade C: Good	polishing	[ ] Duplicate publication	publication
[ ] Grade D: Fair	[ ] Grade C: A great deal of	[ ] Plagiarism	[ ] Rejection
[ ] Grade E: Poor	language polishing	[ Y ] No	[Y] Minor revision
	[ ] Grade D: Rejected	BPG Search:	[ ] Major revision
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[ Y ] No	

### **COMMENTS TO AUTHORS**

Dear editor The manuscript entitled "Indoleamine 2, 3-dioxygenase: a prognostic marker and immunotherapeutic target for hepatocellular carcinoma" is an informative review article which presents some useful information about the role of Indoleamine 2, 3-dioxygenase in HCV- and HBV-induced HCC. Author have mentioned about the role of occult HBV and I think they can also speak about the role of occult HCV infection in the HCC as this form of HCV cannot be diagnosed easily with usual laboratory approaches I think authors should briefly mention their methods (data resources and search strategy) for performing this review and they can bring it in a separate paragraph in the manuscript. Readers need to know the exact criteria which authors used for bringing a description of each study in table 1. In my idea, the manuscript can be accepted after minor revision.